SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVictrex Regulatory News (VCT)

Share Price Information for Victrex (VCT)

Share Price is delayed by 15 minutes
Get Live Data
620.00    9.00 (1.47%)
Bid:
621.00
Ask:
623.00
Spread: 2.00 (0.322%)
Market Cap: £540.17m
VCT Live PriceLast checked at - London Stock Exchange

Intraday Victrex Share Chart

AGM and Q1 Interim Management Statement

4 Feb 2015 07:00

RNS Number : 9655D
Victrex PLC
04 February 2015
 



 

 

 

 

 

 

4 February 2015

Victrex plc

AGM and Q1 Interim Management Statement

'A solid start to 2015'

Victrex plc, an innovative world leader in high performance polymer solutions, today releases its first quarter (Q1) Interim Management Statement ahead of its Annual General Meeting being held this morning.

Overall, Victrex has seen a solid start to 2015. Group revenue of £59.8m was 14% ahead of the prior year (Q1 2014: £52.4m), with Group sales volume of 967 tonnes 42% ahead of the prior year (Q1 2014: 679 tonnes). The strong volume comparative in Q1 largely reflects current Consumer Electronics business that did not contribute to the prior year quarter. Excluding Consumer Electronics, volume growth in the underlying business was slightly ahead year on year.

In our VPS business, Q1 continued to benefit from Consumer Electronics - in line with our previous guidance - and we now expect the current Consumer Electronics opportunity to continue into the second half of our financial year.

In our Invibio medical business, revenue was weaker in Q1.This reflects some short term impact from the current consolidation in the US medical device industry and we anticipate that Invibio will still make progress over the full year. Our focus for 2015 remains the roll-out of new products into the Spine market, alongside pre-development work for our new product platforms of Dental, Trauma and Knee.

David Hummel, Chief Executive of Victrex, said: "Overall, Victrex has made a solid start to 2015 and our focused strategy is helping to continue our growth momentum. At this early stage of the year, our expectations are unchanged and we remain well placed for the year ahead."

Victrex remains in a strong financial position, with a healthy balance sheet, good cash generation and no significant changes to our financial position since 30 September 2014.

Enquiries:

Victrex plc:

Andrew Hanson, Head of Investor Relations & Communications +44 (0) 7809 595831

Louisa Burdett, Group Finance Director +44 (0) 1253 897700

David Hummel, Chief Executive +44 (0) 1253 897700

 

Pendomer Communications:

Charles Armitstead / Rebecca Hall +44 (0) 203 603 5220

 

About Victrex:

Victrex is an innovative world leader in high performance polymer solutions, focused on the strategic markets of Automotive, Aerospace, Energy, Electronics and Medical. Every day, millions of people rely on products or applications which contain our materials, from smartphones, aeroplanes and cars to oil & gas operations and medical devices. With over 35 years' experience, we are investing in technical excellence to deliver new and leading edge solutions to our customers and our markets, and to drive value for our shareholders. Find out more at www.victrexplc.com

 

Analyst and investor call:

A conference call for analysts and investors will be held this morning at 09.00am. Please contact Laura Stewart at Pendomer Communications for details on +44 (0) 203 603 5220 or laura.stewart@pendomer.com

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSTJMPTMBTMBTA
Date   Source Headline
29th May 202611:00 amRNSTotal Voting Rights
18th May 20268:50 amRNSDirectorate change
11th May 20267:00 amRNSHalf-year Financial Report
30th Apr 202610:46 amRNSTotal Voting Rights
29th Apr 20264:28 pmRNSHolding(s) in Company
31st Mar 20261:37 pmRNSTotal Voting Rights
24th Mar 20264:29 pmRNSHolding(s) in Company
24th Mar 20262:03 pmRNSHolding(s) in Company
20th Mar 20269:38 amRNSHolding(s) in Company
27th Feb 20262:40 pmRNSTotal Voting Rights
27th Feb 20261:02 pmRNSHolding(s) in Company
24th Feb 202611:41 amRNSHolding(s) in Company
17th Feb 20263:06 pmRNSDirector/PDMR Shareholding
12th Feb 20263:26 pmRNSDirector/PDMR Shareholding
12th Feb 20263:22 pmRNSDirector/PDMR Shareholding
10th Feb 20262:43 pmRNSDirector/PDMR Shareholding
10th Feb 20269:00 amRNSDirectorate change
6th Feb 20261:33 pmRNSResult of AGM
6th Feb 20267:00 amRNSQ1 Trading Update
30th Jan 202611:49 amRNSTotal Voting Rights
28th Jan 202612:25 pmRNSHolding(s) in Company
22nd Jan 202610:21 amRNSHolding(s) in Company
20th Jan 20261:26 pmRNSAdditional Listing
31st Dec 20259:00 amRNSTotal Voting Rights
31st Dec 20259:00 amRNSTotal Voting Rights
22nd Dec 202512:00 pmRNSAnnual Financial Report
22nd Dec 202512:00 pmRNSAnnual Financial Report
18th Dec 202511:49 amRNSDirector/PDMR Shareholding - Replacement
17th Dec 20253:42 pmRNSDirector/PDMR Shareholding
17th Dec 202512:08 pmRNSDirector/PDMR Shareholding
15th Dec 20259:00 amRNSDirector/PDMR Shareholding
11th Dec 20258:52 amRNSDirector/PDMR Shareholding
5th Dec 20259:30 amRNSShare purchase by incoming Director (incoming CEO)
4th Dec 20259:06 amRNSFinancial Calendar Update
2nd Dec 20257:00 amRNSPreliminary Results
1st Dec 202510:49 amRNSBlock listing Interim Review
28th Nov 20259:27 amRNSTotal Voting Rights
20th Nov 20259:05 amRNSAdditional Listing
7th Nov 202510:39 amRNSHolding(s) in Company
31st Oct 20258:58 amRNSTotal Voting Rights
21st Oct 20257:30 amRNSCEO Succession update
3rd Oct 202511:36 amRNSHolding(s) in Company
3rd Oct 20259:03 amRNSHolding(s) in Company
30th Sep 20259:54 amRNSTotal Voting Rights
29th Aug 202510:16 amRNSTotal Voting Rights
31st Jul 20259:14 amRNSTotal Voting Rights
9th Jul 20251:02 pmRNSHolding(s) in Company
8th Jul 20253:33 pmRNSDirector/PDMR Shareholding
8th Jul 20257:00 amRNSDirectorate change: CEO succession
8th Jul 20257:00 amRNSQ3 Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.